Published in Radiat Oncol on August 28, 2015
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
Targeted Exome Sequencing Outcome Variations of Colorectal Tumors within and across Two Sequencing Platforms. Next Gener Seq Appl (2016) 0.76
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol (1975) 90.35
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet (2009) 58.77
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 38.62
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Targeted capture and massively parallel sequencing of 12 human exomes. Nature (2009) 33.96
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
A landscape of driver mutations in melanoma. Cell (2012) 12.61
A physical map of the human genome. Nature (2001) 12.39
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res (2014) 10.77
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep (2013) 3.92
Applications of new sequencing technologies for transcriptome analysis. Annu Rev Genomics Hum Genet (2009) 3.59
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res (2010) 2.95
Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science (2013) 2.74
Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov (2013) 2.07
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res (2011) 1.71
Directed evolution of ionizing radiation resistance in Escherichia coli. J Bacteriol (2009) 1.60
Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One (2014) 1.59
DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: implications for radiosensitivity testing. Clin Cancer Res (2008) 1.51
Tracking cancer drugs in living cells by thermal profiling of the proteome. Science (2014) 1.46
Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci U S A (2015) 1.43
The mutational landscape of phosphorylation signaling in cancer. Sci Rep (2013) 1.39
Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys (2009) 1.38
Targeted resequencing of candidate genes using selector probes. Nucleic Acids Res (2010) 1.37
Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle (2012) 1.32
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
Genome-wide analysis of human global and transcription-coupled excision repair of UV damage at single-nucleotide resolution. Genes Dev (2015) 1.28
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol (2014) 1.28
Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet (2011) 1.27
Studying the epigenome using next generation sequencing. J Med Genet (2011) 1.25
Comparison of commercially available target enrichment methods for next-generation sequencing. J Biomol Tech (2013) 1.25
C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res (2014) 1.21
Radiation as an immune modulator. Semin Radiat Oncol (2013) 1.19
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis (2002) 1.15
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2011) 1.08
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol (2011) 1.02
Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res (2012) 1.02
Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis (2006) 0.99
Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J Biol Chem (2002) 0.96
Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget (2014) 0.92
Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiother Oncol (2011) 0.91
Next-generation sequencing and epigenomics research: a hammer in search of nails. Genomics Inform (2014) 0.89
Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse. Int J Radiat Biol (2001) 0.88
c-MYC is a radiosensitive locus in human breast cells. Oncogene (2014) 0.88
Deciphering the RNA landscape by RNAome sequencing. RNA Biol (2015) 0.88
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget (2014) 0.86
Genome Medicine in Cancer: What's in a Name? Cancer Res (2015) 0.85
Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med (2015) 0.84
Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol (2014) 0.79
Feasibility of measuring radiation-induced DNA double strand breaks and their repair by pulsed field gel electrophoresis in freshly isolated cells from the mouse RIF-1 tumor. Int J Radiat Oncol Biol Phys (1996) 0.78
Transplacental mutagenicity of cisplatin: H-ras codon 12 and 13 mutations in skin tumors of SENCAR mice. Carcinogenesis (1996) 0.78
IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiother Oncol (2015) 0.77
Survival Fraction at 2 Gy and γH2AX Expression Kinetics in Peripheral Blood Lymphocytes From Cancer Patients: Relationship With Acute Radiation-Induced Toxicities. Int J Radiat Oncol Biol Phys (2015) 0.77